Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Study Identifier
GMA-COM-09-013
CT.gov Identifier
NCT01170884
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Other
  • Ocular Hypertension
    • Study Drug
  • fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution
  • bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosed with glaucoma or ocular hypertension. * Visual Acuity 20/100 or better in both eyes
    Exclusion Criteria:
    * Any active ocular disease * History of any intraocular surgery or glaucoma laser surgery within 3 months * Contraindication to pupil dilation * Use of topical, periorbital, intravitreal, or systemic steroid within 3 months

    Protocol Summary

    Comparing Safety and Efficacy of Combigan® and Lumigan® with Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated with Xalatan®.

    Study Locations

    Location
    Status
    Location
    Dallas, Texas, United States
    Status
    Not applicable